The incidence of G-CSF administration for agranulocytosis in the acute onset group was 8.0 per 1000 person years (0.2% during the first 72 days), and that in the late onset group was 0.7 per 1000 person-years (Fig. 2D). Here, CSF3 is linked to Absence of circulating granulocytes.